000			01891 a2200481 4500
005			20250516041232.0
264		0	_c20120503
008			201205s 0 0 eng d
022			_a2211-3436
024	7		_a10.1007/s13402-011-0048-2 _2doi
040			_aNLM _beng _cNLM
100	1		_aDuijkers, Floor A M
245	0	0	_aAnaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels. _h[electronic resource]
260			_bCellular oncology (Dordrecht, Netherlands) _cOct 2011
300			_a409-17 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnaplastic Lymphoma Kinase
650	0	4	_aCell Differentiation _xdrug effects
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aExtracellular Signal-Regulated MAP Kinases _xmetabolism
650	0	4	_aGene Dosage
650	0	4	_aGene Expression Regulation, Neoplastic _xdrug effects
650	0	4	_aHumans
650	0	4	_aMutation _xgenetics
650	0	4	_aNeuroblastoma _xdrug therapy
650	0	4	_aNeurons _xdrug effects
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aPyrimidines _xpharmacology
650	0	4	_aRNA, Messenger _xgenetics
650	0	4	_aReceptor Protein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aSchwann Cells _xdrug effects
650	0	4	_aSignal Transduction _xdrug effects
700	1		_aGaal, José
700	1		_aMeijerink, Jules P P
700	1		_aAdmiraal, Pieter
700	1		_aPieters, Rob
700	1		_ade Krijger, Ronald R
700	1		_avan Noesel, Max M
773	0		_tCellular oncology (Dordrecht, Netherlands) _gvol. 34 _gno. 5 _gp. 409-17
856	4	0	_uhttps://doi.org/10.1007/s13402-011-0048-2 _zAvailable from publisher's website
999			_c20886102 _d20886102